UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $959,000 Holdings in Zenas BioPharma, Inc. $ZBIO

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 143.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,790 shares of the company’s stock after buying an additional 22,267 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Zenas BioPharma were worth $959,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Zenas BioPharma by 25.0% during the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after acquiring an additional 290,307 shares during the period. Walleye Capital LLC acquired a new position in Zenas BioPharma in the 2nd quarter worth approximately $5,306,000. NEXTBio Capital Management LP purchased a new position in Zenas BioPharma during the 4th quarter worth approximately $11,691,000. Bank of America Corp DE grew its position in Zenas BioPharma by 723.5% during the 1st quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock worth $7,592,000 after purchasing an additional 341,187 shares in the last quarter. Finally, J. Goldman & Co LP purchased a new position in Zenas BioPharma during the 2nd quarter worth approximately $1,732,000.

Zenas BioPharma Stock Up 0.1%

Zenas BioPharma stock opened at $31.12 on Friday. Zenas BioPharma, Inc. has a twelve month low of $13.50 and a twelve month high of $44.60. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The firm has a market cap of $2.03 billion, a PE ratio of -3.46 and a beta of -1.04. The firm’s 50 day moving average price is $31.16 and its two-hundred day moving average price is $24.71.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The business had revenue of $1.00 million for the quarter, compared to the consensus estimate of $15.00 million. On average, research analysts predict that Zenas BioPharma, Inc. will post -5.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on ZBIO shares. Wedbush restated an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a report on Friday, August 14th. Guggenheim reiterated a “buy” rating and set a $55.00 price target on shares of Zenas BioPharma in a report on Friday, August 14th. Morgan Stanley upped their price target on Zenas BioPharma from $22.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and an average price target of $45.71.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.